Jul 21, 2025 04:38PM CERo Therapeutics (CERO) Files for 12.5M Share Offering by Selling Stockholders

Jun 23, 2025 07:01AM D. Boral Capital Upgrades Cero Therapeutics (CERO) to Buy

Jun 17, 2025 08:15AM CERo Therapeutics (CERO) Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia

Jun 11, 2025 09:10AM CERo Therapeutics (CERO) Announces Reverse Stock Split

Jun 6, 2025 08:15AM CERo Therapeutics (CERO) Announces Option Exercise for Additional Series D Financing

Jun 2, 2025 09:05AM CERo Therapeutics (CERO) Granted Two U.S. Patents and European Patent Application Allowance Regarding Company’s Lead Compound

May 30, 2025 08:16AM CERo Therapeutics (CERO) Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations

May 19, 2025 10:40AM Maxim Group Starts Cero Therapeutics (CERO) at Buy

May 8, 2025 08:15AM CERo Therapeutics (CERO) Regains Nasdaq Compliance

Apr 30, 2025 08:15AM CERo Therapeutics (CERO) Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Trial of CER-1236

Apr 24, 2025 08:17AM CERo Therapeutics (CERO) Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236

Apr 22, 2025 08:15AM CERo Therapeutics (CERO) Announces Up to $8M Series D Financing

Apr 22, 2025 07:04AM D. Boral Capital Starts Cero Therapeutics (CERO) at Buy

Apr 10, 2025 08:16AM CERo Therapeutics (CERO) Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company’s Lead Compound CER-1236

Apr 10, 2025 08:15AM CERo Therapeutics (CERO) Announces Critical Patent Application Allowances from the U.S. Patent Office for CER-1236

Mar 31, 2025 08:15AM CERo Therapeutics (CERO) Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of CER-1236

Mar 27, 2025 08:15AM CERo Therapeutics (CERO) to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing

Mar 19, 2025 08:15AM CERo Therapeutics (CERO) Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services

Mar 13, 2025 08:15AM CERo Therapeutics (CERO) Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Sol

Mar 13, 2025 08:15AM CERo Therapeutics (CERO) Presents Encouraging Preclinical Data for CER-1236

Mar 6, 2025 08:15AM CERo Therapeutics (CERO) Announces Progress in Initiation of Phase 1 Clinical Trial

Feb 6, 2025 08:15AM CERo Therapeutics (CERO) Highlights Progress

Jan 6, 2025 08:07AM CERo Therapeutics (CERO) Announces 1:100 Reverse Share Split

Nov 27, 2024 06:24AM CERo Therapeutics (CERO) Files for 210M Share Offering by Selling Stockholders

Nov 15, 2024 08:45AM CERo Therapeutics (CERO) Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

Nov 11, 2024 08:16AM CERo Therapeutics (CERO) Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

Oct 21, 2024 09:00AM CERo Therapeutics (CERO) Provides Corporate Update

Oct 2, 2024 09:15AM CERo Therapeutics (CERO) Appoints Al Kucharchuk as CFO, Kristen Pierce as Chief Development Officer

Sep 25, 2024 09:19AM CERo Therapeutics (CERO) Announces Financing and Provides Update on Investigational New Drug Application for CER-1236

Jun 27, 2024 05:39PM CERo Therapeutics (CERO) Files for 44.13M Share Offering by Selling Stockholders

Jun 13, 2024 08:23AM CERo Therapeutics (CERO) Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236